Cellectar’s IopofosineI 131 receives US FDA breakthrough therapy designation for treating Waldenstrom macroglobulinemia: Florham Park, New Jersey Friday, June 6, 2025, 17:00 Hrs ...

Cellectar Biosciences ( ($CLRB) ) just unveiled an update. On June 5, 2025, Cellectar Biosciences entered into agreements to raise $2.5 million ...

Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and ...

Real-time index price for Nasdaq Global Market Composite Index (NQGM), along with buy or sell indicators, analysis, charts, ...

Shares of Cellectar Biosciences Inc (NASDAQ:CLRB) surged 63.5% following the announcement that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for its cancer ...

Cellectar's Iopofosine I 131 earned FDA breakthrough therapy designation for relapsed Waldenstrom macroglobulinemia following ...

Designation Supported by CLOVER WaM Phase 2 Study DataWhich Reported an 83.6% Overall Response Rate (ORR) Seeking Guidance ...

Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on rebalancing inflammation to optimize health, announced the ...

SOUTH SAN FRANCISCO, Calif. & SAN DIEGO--(BUSINESS WIRE)--May 22, 2025-- ...

OpenAI’s Sam Altman has poured millions into the longevity-focused Retro Biosciences. Sean Gallup/Getty Images ...